Odyssey Therapeutics
PublicOdyssey Therapeutics is now publicly traded
The data on this page reflects Odyssey Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
May 7, 2026
Last Round
Series D
Sep 10, 2025
Total Funding Raised
$1.11B
Company Overview
Odyssey Therapeutics is a biotechnology company that develops precision immunomodulators and oncology medicines to treat autoimmune and inflammatory diseases.
Sector
Biotech
AI Layer
Application
Keywords
Odyssey Therapeutics Comparables
Compare Odyssey Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Treeline Biosciences | 89% | |
| Eikon Therapeutics | 81% | |
| Mirador Therapeutics | 80% |
Odyssey Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | May 7, 2026 | ||||
| Series D | Sep 10, 2025 | ||||
| IPO | Jan 17, 2025 | ||||
| Series C | Dec 5, 2023 | ||||
| Series B | Oct 13, 2022 | ||||
Series A | Dec 7, 2021 |
Key People
Founding team and executive leadership
Odyssey Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GreatPoint Ventures | Series B |
| CPP Investments | Series C |
| Wedbush Healthcare Partners | Series D |
| KB Investment | Series C |
| Frontline BioVentures | Series B, Series C, Series A |
| KB Investment | Series C |
| Creacion Ventures | Series B, Series C, Series A, Series D |
Odyssey Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access